Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies - Wacker, B; Nagrani, T; Weinberg, J (Clinical cancer research: an official journal of the American Association for Cancer Research, 2007)
et al.